Larviciding to control malaria by Choi, Leslie & Wilson, Anne
Cochrane Database of Systematic Reviews
Larviciding to control malaria (Protocol)
Choi L, Wilson A
Choi L, Wilson A.
Larviciding to control malaria.
Cochrane Database of Systematic Reviews 2017, Issue 7. Art. No.: CD012736.
DOI: 10.1002/14651858.CD012736.
www.cochranelibrary.com
Larviciding to control malaria (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
4OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iLarviciding to control malaria (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Protocol]
Larviciding to control malaria
Leslie Choi1a , Anne Wilson2b
1Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK. 2Department of Biosciences, Durham
University, Durham, UK
aThese authors contributed equally to this work. bThese authors contributed equally to this work
Contact address: Leslie Choi, Department of Clinical Sciences, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3
5QA, UK. leslie.choi@lstmed.ac.uk.
Editorial group: Cochrane Infectious Diseases Group.
Publication status and date: New, published in Issue 7, 2017.
Citation: Choi L,WilsonA. Larviciding to controlmalaria.Cochrane Database of Systematic Reviews 2017, Issue 7. Art. No.: CD012736.
DOI: 10.1002/14651858.CD012736.
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To evaluate whether larviciding controls malaria transmission.
B A C K G R O U N D
Description of the condition
Malaria is caused by the Plasmodium parasite, which is transmitted
by femaleAnophelesmosquitoes. There are fivePlasmodium species
that cause disease in humans; however, the most important species
in terms of disease burden are Plasmodium falciparum, which is
prevalent in sub-Saharan Africa, and Plasmodium vivax, which is
more common in central Asia and South America. There were an
estimated 212 million malaria cases and 429,000 deaths world-
wide due to malaria in 2015 (WHO 2016). Sub-Saharan Africa
carries a disproportionately high share of the malaria burden, with
90% of cases and 92% of malaria deaths in 2015 (WHO 2016).
In high transmission areas, children under five years old are highly
susceptible to malaria infection, illness, and death, and accounted
for 70% of all malaria deaths in 2015 (WHO 2016). As well as
direct effects on health, malaria is a major cause of poverty and un-
derdevelopment in many countries, due to household and health
system costs, absenteeism from school or work, reduced productiv-
ity, and premature death (Chima 2008). Malaria-endemic coun-
tries are, on average, poorer by more than five-fold and have lower
rates of economic growth than non-malaria endemic countries,
with an average growth of per-capita GDP of 0.4% per year versus
2.3% between 1965 and 1990 (Sachs 2002).
Vector control tools, such as long-lasting insecticidal nets (LLINs)
and indoor residual spraying (IRS) of insecticide, play a large role
in malaria control, alongside diagnosis and effective treatment of
malaria cases, and chemoprevention in some population groups.
Scale-up of vector control and diagnosis and treatment has averted
663 million clinical cases of malaria between 2000 and 2015 (
Bhatt 2015). However, a high burden of morbidity and mortality
still remains and the World Health Organization (WHO) set out
ambitious targets in the Global Technical Strategy to eliminate
malaria in at least 35 countries by 2030 (WHO 2016).
Description of the intervention
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Larviciding refers to the regular application of microbial or chem-
ical insecticides to water bodies or water containers to kill the
aquatic immature forms of the mosquito (the larvae and pupae)
(Tusting 2013).
Mosquitoes lay their eggs in standing water and the eggs develop
through a series of life stages (larvae and pupae) into adults. The
type of standing water selected by ovipositing females depends on
the species in question and can be natural or man-made, tempo-
rary or permanent (Bruce-Chwatt 1985). For example, Anopheles
stephensi prefers containers such as water tanks, some species pre-
fer brackish habitats (Anopheles aquasalis in Latin America), while
others prefer riceland habitats (Anopheles arabiensis).
There are a number of different types of larvicide, including in-
secticides, insect growth regulators, microbial larvicides, and oils.
Larvicides have varying modes of action. For example, surface
films, such as mineral oils and alcohol-based surface products, suf-
focate the mosquito larvae and pupae by covering the surface of
a water body. This is different from synthetic organic chemicals,
such as organophosphates (the most widely used being temephos)
which inhibit cholinesterase and affect the central nervous system
of the mosquito. Insect growth regulators (such as pyriproxyfen,
methoprene, and diflubenzuron) interfere with insect metamor-
phosis and prevent adult emergence from the pupal stage. Micro-
bial larvicides (such as Bacillus thuringiensis israeliensis (Bti) and
Bacillus sphaericus (Bs)) function by releasing toxins into the larvae
gut which cause the larvae to stop eating and die (WHO 2013).
How the intervention might work
Larviciding aims to reduce malaria transmission by targeting the
immature stages (larvae and pupae) of the anophelinemosquito, to
reduce the number of mosquitoes that reach adulthood. By reduc-
ing adult vector populations in this fashion, larviciding can reduce
the transmission of Plasmodium spp. by anopheline mosquitoes,
and reduce morbidity and mortality from malaria (Figure 1).
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Figure 1. A logic model that describes the proposed effect of larviciding on various entomological and
epidemiological outcomes. Abbreviations: EIR: entomological inoculation rate
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Many of the principles behind vector control come from the the-
ory of vectorial capacity developed by George Macdonald in the
1950s (Macdonald 1957). Vectorial capacity describes the total
number of potentially infectious bites that would eventually arise
from all the mosquitoes biting a single perfectly infectious (that
is, all mosquito bites result in infection) human on a single day.
Vectorial capacity can be linked to the basic reproduction ratio
of a disease which is the estimated number of secondary infec-
tions potentially transmitted by a single infected individual in a
totally susceptible population (Black 1968). The basic reproduc-
tion number represents the theoretical estimate of the intensity of
transmission. The George-Macdonald model shows that vectorial
capacity is most sensitive to changes in adult mosquito survival,
which led to the prioritization of IRS and LLINs as vector control
tools in the 1950s. However, the vectorial capacity model does not
adequately consider the aquatic stages of the vector and so the po-
tential of larviciding is likely to have been underestimated (Brady
2016). Models show that larval source management (LSM) re-
duces mosquito population density linearly with coverage if adult
mosquitoes avoid laying eggs in treated habitats, but quadratically
if eggs are laid in treated habitats and the effort is therefore wasted
(Smith 2013). This would mean that if the most productive habi-
tats are targeted, larviciding could be highly effective even with-
out extensive coverage, unlike previously thought. Larviciding can
also operate against both indoor and outdoor (for example, An.
arabiensis) biting and resting mosquitoes, unlike LLINs and IRS.
This is beneficial since in some settings, anthropophillic vectors
are able to sustain transmission even with high coverage of LLINs
or IRS, or both (Bayoh 2010; Russell 2010; Lwetoijera 2014), and
several studies have also shown evidence of behavioural adaptation
of vectors towards early evening biting which can reduce the ef-
fectiveness of indoor interventions (Gatton 2013). Thus larvicid-
ing can be effective against ’residual malaria transmission’, which
is generally defined as transmission that exists despite universal
coverage of LLINs or IRS to which vector populations are fully
susceptible (Durnez 2013; Killeen 2014).
Why it is important to do this review
There is a need for new tools in malaria vector control if the goals
set by the WHO Global Technical Strategy are to be achieved
(WHO 2016). Malaria vector control currently relies largely on
LLINs and IRS. Although the WHO recommends the use of
LSM (including larviciding) as a supplementary control measure
(WHO 2013), larviciding is not widely used by malaria control
programmes. This is also despite historical success with the use of
larviciding for vector control. Paris Green, a arsenic-based com-
pound toxic to larvae, contributed to the elimination of species
belonging to the Anopheles gambiae complex in Egypt and Brazil
(Soper 1943; Shousha 1948). Larviciding has also been hugely
successful against other vector-borne diseases; for example, Bti and
temephos were used to control species of the Simulium damnosum
complex - vectors of onchocerciasis - in Brazil and the continent
of Africa as a supplement to mass drug administration (MDA)
(Sékétéli 2002; Gustavsen 2011).
Larviciding has the potential to overcome several challenges cur-
rently facing malaria vector control. Firstly, larviciding is able to
target outdoor resting and biting mosquitoes that are less affected
by LLINs and IRS. Secondly, it could be used to tackle residual
foci of malaria where high coverage of LLINs and IRS is not suf-
ficient to eliminate malaria. Lastly, larviciding could be used in
tandemwith other interventions as part of an insecticide resistance
management strategy. Insecticide resistance has been reported in
all major malaria vectors and involves all classes of insecticide (but
particularly pyrethroids) and may threaten the effectiveness of in-
secticide-based vector control (WHO 2012). The distribution and
intensity of insecticide resistance has been increasing over time.
Of 73 malaria-endemic countries reporting insecticide resistance
monitoring data since 2010, 60 reported resistance to at least one
insecticide class and 50 reported resistance to two or more insec-
ticide classes (WHO 2016). The WHO Global Plan for Insecti-
cide Resistance Management recommends the use of insecticide-
based and non-insecticide-based interventions targeting both im-
mature and adult mosquitoes as an insecticide resistance manage-
ment strategy. This is also aligned with Integrated Vector Man-
agement (IVM), an adaptive, evidence-based, and multisectorial
approach to vector control, which is recommended by the WHO
for more effective, sustainable, and ecologically sound vector con-
trol (WHO 2008).
A Cochrane Review of LSM for controlling malaria already exists,
which led to the WHO recommendation on LSM as a supple-
mentary malaria vector control intervention and the publication
of a WHO operational manual on LSM (Tusting 2013; WHO
2013). Although all LSM interventions have the aim of reducing
mosquito larvae, the ways they are carried out are very different
and effectiveness is likely to differ. For example, habitat modifica-
tion (a permanent alteration to the environment such as drainage
of aquatic habitats) is different to regular application of larvicides
to a water body. Due to such differences in different components
of LSM, a new assessment of larviciding alone is justified, thus
splitting the original Cochrane Review on LSM (Tusting 2013).
O B J E C T I V E S
To evaluate whether larviciding controls malaria transmission.
M E T H O D S
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Criteria for considering studies for this review
Types of studies
• Randomized controlled trials (RCTs) with: (a) the unit of
randomization being a cluster, and (b) at least two clusters per
arm. As larvicides are distributed at a community level, we do
not expect to find trials with individual randomization.
• Randomized cross over trials with: (a) the unit of
randomization being a cluster, (b) at least two clusters per arm,
and (c) a suitable washout period during which malaria or
entomological indices have returned to baseline levels. As
larvicides are distributed at a community level, we do not expect
to find trials with individual randomization.
• Controlled before-and-after studies (CBAs) with: (a) a
contemporaneous control group, and (b) at least two sites per
arm.
• Interrupted time series (ITS) studies with: (a) a clearly
defined point in time when the intervention occurred, and (b) at
least three data points before and three during or after cessation
of larviciding.
We will exclude studies if we observe the following.
• The intervention was applied for less than one year in trials
with perennial (year-round) transmission (as reported by the
study authors); or less than one transmission season (defined as
the period from the onset of rains until one month afterwards) in
trials with seasonal transmission (as reported by the study
authors).
• The follow-up periods for the intervention and control
periods were not identical.
Types of participants
All people living in a rural or urban malarious area that is at any
level of endemicity, including both stable and unstable transmis-
sion.
We will include studies specific to special groups, such as refugees
and soldiers, but we will group and analyse them separately.
Types of interventions
Intervention arm
Larviciding interventions that include insecticides, insect growth
regulators, microbial larvicides, or oils.Wewill exclude plant prod-
ucts, because formulations have not been standardized and stud-
ies are thus not comparable. We will also exclude larvivorous fish,
since this is a topic of a separate Cochrane Review (Walshe 2013).
Control
Not receiving larviciding interventions as described above. Any co-
interventions such as LLINs, IRS, topical repellents, spatial repel-
lents, environmental manipulation, environmental modification,
MDA, and case management must be received in both control
and intervention arms.
Types of outcome measures
Studies must report at least one primary outcome for inclusion in
the Cochrane Review.
Primary outcomes
• Clinical malaria incidence: we will use site-specific
definitions, provided they include: (a) demonstration of malaria
parasites by blood smear or a rapid diagnostic test (RDT), or
both; and (b) clinical symptoms including fever detected
passively or actively.
• Malaria parasitaemia incidence: measured as a count per
person unit time of (a) infections or (b) new infections,
following treatment to avoid measuring pre-existing infections.
Infection is defined as parasitaemia confirmed by blood smear
microscopy or RDT.
• Malaria parasite prevalence: the proportion of surveyed
individuals with confirmed parasitaemia.
Secondary outcomes
Entomological
• Entomological Inoculation Rate (EIR): the estimated
number of bites by infectious mosquitoes per person per unit
time. This is measured using the human biting rate (the number
of mosquitoes biting an individual over a stated time period
measured directly using human baits or indirectly using light
traps, knock-down catches, baited huts, or other methods of
biting rate determination) multiplied by the sporozoite rate.
• Adult mosquito density measured by a technique previously
shown to be appropriate for the vector (measured using human
baits, light traps, knock-down catches, baited huts, or other
methods). Adult mosquito density will most likely be reported as
bites/person/night for human landing catches and mosquitoes/
traps/night for trap catches or pyrethrum spray catches.
• Sporozoite rate.
Epidemiological
• Incidence of severe malaria: we will use site specific
definitions, provided they include (a) and either (b) or (c):
◦ (a) demonstration of parasitaemia by blood smear;
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◦ (b) symptoms of cerebral malaria including coma or
prostration or multiple seizures, or both;
◦ (c) severe life-threatening anaemia (WHO 2015).
• Malaria-related deaths.
• Mean haemoglobin levels (g/dL).
• Anaemia prevalence defined as per WHO cut-offs (WHO
2011).
• Hospital admissions for malaria.
Adverse events
Any indicators of adverse events of the intervention, including the
following.
• Non-target effects such as the larvicide killing other animals
in the water body.
• Reports of poisoning in humans due to increased exposure
to larviciding chemicals.
• Environmental impacts such as changes to the biodiversity
and ecosystem due to the addition of larvicides.
Search methods for identification of studies
Wewill attempt to identify all relevant trials regardless of language
or publication status (published, unpublished, in press, and in
progress).
Electronic searches
We will search the following databases using the search terms and
strategy described in Appendix 1: the Cochrane Infectious Dis-
eases Group Specialized Register; the Cochrane Central Register
of Controlled Trials (CENTRAL), published in the Cochrane Li-
brary; MEDLINE (Pubmed); Embase (OVID); CABS Abstracts
(Web of Science); and LILACS (BIREME).Wewill also search the
WHO International Clinical Trials Registry Platform (ICTRP)
(http://www.who.int/ictrp/en/) and ClinicalTrials.gov (https://
clinicaltrials.gov/ct2/home) for trials in progress, using “malaria“,
”mosquito“, and ”larvicid*“ as search terms.
Searching other resources
Wewill handsearch theUSArmed Forces PestManagement Board
Defense Pest Management Literature Retrieval System and the
Tropical Diseases Bulletin using the terms: malaria or mosquito
and larvicides, from January 2011 to present. Tusting 2013 hand-
searched these sources up to the end of 2010 and incorporated the
results into the Cochrane Review ’Mosquito larval source man-
agement for controlling malaria’.
We will contact researchers in the field to identify unpublished
data, and we will check the reference lists of studies identified by
the above methods.
Data collection and analysis
Selection of studies
Two review authors (LC and AW) will independently assess the
titles and abstracts of trials identified by the literature searches.We
will obtain the full-text articles of any potentially relevant articles
identified by at least one of the review authors. The same two
review authors will assess the full-text articles of potentially rele-
vant studies for inclusion using an eligibility form based on pre-
determined inclusion criteria. We will resolve any disagreements
by discussion and consensus, with arbitration by a third review
author if necessary. We will ensure that multiple publications of
the same trial are included once. We will list studies excluded after
full-text assessment, together with their reasons for exclusion, in
a ’Characteristics of excluded studies’ table. We will illustrate the
study selection process in a PRISMA diagram.
Data extraction and management
Two review authors (LC and AW) will independently extract in-
formation from the trials using prepiloted electronic data extrac-
tion forms. In case of differences in extracted data, the two review
authors will discuss these differences to reach consensus. If un-
resolved, further discussion will involve a third review author. In
case of missing data, we will contact the original study author(s)
for clarification
We will extract the following data.
• Trial design: type of trial; method of participant selection;
adjustment for clustering (for cluster-RCTs); sample size;
method of blinding of participants and personnel.
• Participants: trial settings and population characteristics;
recruitment rates; withdrawal and loss to follow-up.
• Intervention: description of intervention (active ingredient,
dose, formulation, method, frequency and timing of application,
buffer zone between clusters); quality control of the larvicide (for
example, WHO Pesticide Evaluation Scheme (WHOPES)
approved); quality assurance of implementation of larviciding;
co-interventions; description of control; duration of follow-up;
passive or active case detection; coverage of larvicide (as reported
by the study authors) and co-interventions (for example, vector
control, vaccines, chemoprophylaxis, diagnosis and treatment);
duration of the activity of the larvicide; compliance (with
application of larvicide and co-interventions).
• Outcomes: definition of outcome; diagnostic method or
surveillance method; number of events; number of participants
or unit time; time point at which outcome was assessed in
relation to larviciding implementation, statistical power; unit of
analysis; incomplete outcomes or missing data.
• Other:
◦ primary and secondary vector(s) species; vector(s)
behaviour (nature, stability and extent (number and size) of
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aquatic habitats, proximity of aquatic habitats to human
habitation, adult habitat, peak biting times, exophilic/
endophilic, exophagic/endophagic, anthropophilic/zoophilic);
method of mosquito collection(s); phenotypic insecticide
resistance (based on WHO definitions if supplementary WHO
cylinder assays or CDC bottle bioassays, or both, were
performed whilst the trial was running, alternatively intensity
assays or synergist assays); genotypic insecticide resistance profile
(either performed during the trial or if the trial references data
from previous studies done on the same local vector population
within the previous five years); insecticide and larvicide resistance
detected in the larvae (as reported by study authors);
◦ malaria endemicity; eco-epidemiological setting;
population proximity and density; Plasmodium species.
For dichotomous outcomes, we will extract the number of partic-
ipants experiencing each outcome and the number of participants
in each treatment group. For count data outcomes, we will extract
the number of outcomes in the treatment and control groups, and
the total person time at risk in each group or the rate ratio, and
a measure of variance (for example, standard error). For continu-
ous outcomes, we will extract the mean and a measure of variance
(standard deviation).
For cluster-RCTs we will record the number of clusters random-
ized; number of clusters analysed; measure of effect (such as risk
ratio (RR), odds ratio, or mean difference (MD)) with confidence
intervals (CI) or standard deviations; number of participants; and
the intracluster correlation coefficient (ICC) value.
For non-randomized studies, we will extract adjusted measures of
intervention effects that attempt to control for confounding.
Assessment of risk of bias in included studies
Two review authors (LCandAW)will independently assess the risk
of bias for each included cluster-RCT using the Cochrane ’Risk
of bias’ tool and the five additional criteria listed in Section 16.3.2
of the Cochrane Handbook for Systematic Reviews of Interventions
that relate specifically to cluster-RCTs (Higgins 2011a; Higgins
2011b). For assessing the risk of bias for randomized cross-over
trials, we will use the Cochrane ’Risk of bias’ tool also and the
additional criteria listed in Section 16.4.3 of the Cochrane Hand-
book for Systematic Reviews of Interventions that relate specifically to
randomized cross-over trials (Higgins 2011a). We will assess non-
randomized controlled studies and ITS trials for risk of bias using
Cochrane Effective Practice and Organisation of Care (EPOC)
’Risk of bias’ tool. We will resolve any discrepancies through dis-
cussion or by consulting a third review author. We will classify
judgements of risk of bias as either at low, high, or unclear risk of
bias, and we will use summary graphs (’Risk of bias’ summary and
’Risk of bias’ graph) to display results.
Measures of treatment effect
We will compare intervention and control data using RRs if the
outcome is dichotomous. We will present rate data as rate ratios.
We will calculate the MD for continuous measures. We will use
adjusted measures of effect to summarize treatment effect from
non-randomized studies. We will present all results with their as-
sociated 95% CIs.
We will report any accounts that signal adverse effects. We appre-
ciate that the specified inclusion criteria are not designed to detect
effects on animals in the water, people exposed to the larvicides,
and the ecosystem overall, and we will note this in the discussion.
Unit of analysis issues
For cluster-RCTs, we will extract adjusted measures of effect where
possible. If the study authors did not perform any adjustment
for clustering, we will adjust the raw data using an ICC value.
If an ICC value is not reported in the study, we will contact the
study authors for this ICC, obtain this from similar studies, or
estimate the ICC. We will not present results from cluster-RCTs
that are not adjusted for clustering. If we estimate the ICC, we
will perform sensitivity analyses to investigate the robustness of
our analyses. If we identify studies for inclusion that havemultiple
intervention arms, wewill include data from these studies by either
combining treatment arms, or by splitting the control group so
that participants are only included in the meta-analysis once (
Richardson 2016).
For randomized cross-over trials, we will apply the principles stated
in Section 16.4.3 of the Cochrane Handbook for Systematic Reviews
of Interventions that relate specifically to randomized cross-over
trials (Higgins 2011a).
Dealing with missing data
In case of missing data, we will apply available-case analysis and
will only include data on the known results. The denominator will
be the total number of participants who had data recorded for the
specific outcome. For outcomes with no missing data, we plan to
perform analyses on an intention-to-treat basis. We will include
all participants randomized to each group in the analyses and will
analyse participants in the group to which they were randomized.
Assessment of heterogeneity
We will inspect forest plots for overlapping CIs and will assess
statistical heterogeneity in each meta-analysis using the I² statis-
tic and Chi² test. We will regard heterogeneity as moderate if I²
statistic values are between 30% to 60%; substantial if they are
between 50% to 90%; and considerable if they are between 75%
to 100%. We will regard a Chi² test statistic with a P value≤ 0.10
indicative of statistically significant heterogeneity. We will explore
clinical and methodological heterogeneity through consideration
of the trial populations, methods, and interventions, and by visu-
alization of trial results.
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If there is considerable heterogeneity i.e. an I² statistic value of
75% to 100% or inconsistency in the direction of the effect, or
both, then we will not perform a meta-analysis.
Assessment of reporting biases
If there are 10 or more trials included in each meta-analysis, we
will investigate reporting biases (such as publication bias) using
funnel plots. We will assess funnel plot asymmetry visually, and
use formal tests for funnel plot asymmetry (Harbord 2006). If we
detect asymmetry in any of these tests or by a visual assessment,
we will explore the reasons for asymmetry.
Data synthesis
We will analyse data using Review Manager 5 (RevMan 5)
(RevMan 2014). We will use a fixed-effect meta-analysis to com-
bine data if heterogeneity is absent. If considerable heterogeneity
is present, we will combine data using a random-effects meta-anal-
ysis and report an average treatment effect.We will decide whether
to use a fixed- or random-effects model based on the considera-
tion of clinical and methodological heterogeneity between trials,
as described previously.
We will pool data across follow-up time points for each included
study.
Certainty of the evidence
We will assess the certainty of evidence using the GRADE ap-
proach (Guyatt 2011). We will rate each important outcome as
described by Balshem 2011.
• High: we are very confident that the true effect lies close to
that of the estimate of the effect.
• Moderate: we are moderately confident in the effect
estimate. The true effect is likely to be close to the estimate of
the effect.
• Low: our confidence in the effect estimate is limited. The
true effect may be substantially different from the estimate of the
effect.
• Very low: we have very little confidence in the effect
estimate. The true effect is likely to be substantially different
from the estimate of effect.
RCTs start as high quality evidence but can be downgraded if
there are valid reasons within the following five categories: risk
of bias, imprecision, inconsistency, indirectness, and publication
bias. Studies can also be upgraded if there is a large effect, a dose
response effect, and if all plausible residual confounding would
reduce a demonstrated effect or would suggest a spurious effect if
no effect was observed (Balshem 2011). We will summarize our
findings in a ’Summary of findings’ table.
Subgroup analysis and investigation of heterogeneity
We will initially analyse all types of larvicide (for example, sur-
face films, synthetic organic chemicals, insect growth regulators,
microbial larvicides) together. If there are a sufficient number of
studies then we will group these and analyse them separately.
We will explore reasons for substantial heterogeneity using sub-
group analysis. We plan to perform the following subgroup anal-
yses.
• Seasonality of malaria:
◦ perennial, defined as year-round transmission;
◦ seasonal (a) as reported by study authors in the
manuscript or (b) defined as 75% or more of all malaria episodes
occurring in six or less months of the year (Roca-Feltrer 2009);
◦ epidemic, defined as a sharp rise in malaria incidence,
higher than typical levels.
• Extent of aquatic habitat:
◦ container habitat;
◦ habitats smaller than 1 km² (excluding containers);
◦ habitats larger than 1 km.
• Continent:
◦ Africa;
◦ non-Africa.
Sensitivity analysis
Wewill perform sensitivity analysis on the primary outcome to see
the effect of exclusion of trials at high risk of bias (for allocation
concealment and incomplete outcome data) on the overall results.
If the ICC value is estimated, we will undertake sensitivity analyses
to investigate the impact of varying the ICC value onmeta-analysis
results.
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A P P E N D I C E S
Appendix 1. Detailed search strategy
Search set CIDG SR1 CENTRAL MEDLINE Embase LILACS CABS Abstracts
1 Mosquito* Malaria [ti, ab,
Mesh]
Malaria [ti, ab,
Mesh]
Malaria [ti, ab,
Emtree]
Mosquito$ Mosquito*
2 Anopheles Anopheles [Mesh] Anopheles [ti, ab,
Mesh]
Anopheles ti, ab,
Emtree
Anopheles Anopheles
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(Continued)
3 malaria Mosquito* ti, ab Mosquito* ti, ab Mosquito* ti, ab malaria malaria
4 1 or 2 or 3 Mosquito control
[Mesh]
Mosquito control
[Mesh]
Mosquito control
ti, ab
1 or 2 or 3 1 or 2 or 3
5 Larvicid* 1 or 2 or 3 or 4 1 or 2 or 3 or 4 1 or 2 or 3 or 4 Larvicid$ or larval
or larva or larvae ti,
ab
Larvicid* or larval
or larva or larvae ti,
ab
6 4 and 5 Larvicid* or larval
or larva or larvae ti,
ab
Larvicid* or larval
or larva or larvae ti,
ab
Larvicid* or larval
or larva or larvae ti,
ab
4 and 5 Bacillus
thuringiensis
7 - ”Larval control“ ti,
ab
”Larval control“ ti,
ab
”Larval control“ ti,
ab
- Bacillus sphericus
8 - 6 or 7 Bacillus
thuringiensis [ti,
ab, Mesh]
Bacillus
thuringiensis ti, ab
- Paris green
9 - 5 and 8 Bacillus sphericus
ti, ab
Bacillus sphericus
ti, ab
- Temefos
10 - - Paris green ti, ab,
sn
Paris green ti, ab - Pyriproxyfen
ormethopreneOR
fenthion OR abate
OR ”surface oils“
OR ”surface films“
OR chlor-
pyrifos OR pirim-
iphos-methyl
OR diflubenzuron
OR novaluron OR
spinosad
11 - - Temefos ti, ab, sn Temefos ti, ab - Insect growth reg-
ulator*
12 - - (Pyriproxyfen
ormethopreneOR
fenthion OR abate
OR ”surface oils“
OR ”surface films“
OR chlor-
pyrifos OR pirim-
iphos-methyl
OR diflubenzuron
OR novaluron OR
spinosad) ti, ab
(Pyriproxyfen
ormethopreneOR
fenthion OR abate
OR ”surface oils“
OR ”surface films“
OR chlor-
pyrifos OR pirim-
iphos-methyl
OR diflubenzuron
OR novaluron OR
spinosad) ti, ab
- Biological pest
control
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(Continued)
13 - - Juvenile hormones
[Mesh]
Insect growth reg-
ulator* ti, ab
- 5-12/OR
14 - - Insect growth reg-
ulator* ti, ab
Biological pest
control [Emtree]
- 4 AND 13
15 - - Pest Control, Bio-
logical [Mesh]
Larvicidal agent
[Emtree]
- -
16 - - 6-15/OR 6-15/OR - -
17 - - 5 AND 16 5 AND 16 - -
18 - - - - - -
1Cochrane Infectious Diseases Group Specialized Register.
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